- Office-hours : 9:00 AM to 5:00 PM USA CST
In 2026, pharmacovigilance systems are more digital, more decentralized, and more interconnected than ever. Yet one risk continues to be underestimated across organizations — especially during inspections. It’s not always your core safety vendor. It’s the vendor that was never labeled “PV” in the first place. We’re talking about organizations that interact directly with patients […]
Read More
Suspected Unexpected Serious Adverse Reactions (SUSARs) represent one of the highest regulatory risk areas in clinical development. Health Authorities (HAs) globally, including the FDA, EMA, and national competent authorities, impose strict timelines and documentation expectations for SUSAR identification, assessment, and reporting. Sponsors frequently delegate pharmacovigilance (PV) case processing and regulatory reporting activities to Contract Research […]
Read More
In Good Pharmacovigilance Practices (GVP) Module VI, adverse event reporting is a crucial aspect of ensuring the safety of medicinal products. Here’s an overview of adverse event reporting based on GVP Module VI: 1. Definition of Adverse Event (AE) and Serious Adverse Event (SAE): GVP Module VI typically provides definitions for adverse events and serious […]
Read More
ICH E2B(R3) is a guideline developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This guideline is focused on the standardization of the format, content, and structure of individual case safety reports (ICSRs) for the electronic transmission of safety information for medicinal products, particularly for adverse events (AEs) […]
Read More